Maudy C. W. Gayet

Maudy C. W. Gayet

Auto-generated profile, based on publicly available information

Maudy C. W. Gayet

Department of Urology, Jeroen Bosch Hospital, Henri Dunantstraat 1, 5223 GZ, 's-Hertogenbosch, Netherlands

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2015 in BJU International
Verified
Journal Article
Closed access
PDF file
MGMaudy Gayet
Maudy Gayet
AAAnouk van der Aa
Anouk van der Aa
HBHarrie P. Beerlage
Harrie P. Beerlage
BSBart Ph. Schrier
Bart Ph. Schrier
PMPeter F.A. Mulders
Peter F.A. Mulders
HWHessel Wijkstra
Hessel Wijkstra

1 March 2018 in European Urology Focus
Verified
Journal Article
Closed access
MGMaudy Gayet
Maudy Gayet
CMChristophe K. Mannaerts
Christophe K. Mannaerts
DNDaan Nieboer
Daan Nieboer
HBHarrie P. Beerlage
Harrie P. Beerlage
HWHessel Wijkstra
Hessel Wijkstra
Monique RoobolMonique Roobol
Monique Roobol

20 February 2020 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
APArnoud Wouter Postema
Arnoud Wouter Postema
MGMaudy C. W. Gayet
Maudy C. W. Gayet
RSRuud J. G. van Sloun
Ruud J. G. van Sloun
RWRogier R. Wildeboer
Rogier R. Wildeboer
CMChristophe K. Mannaerts
Christophe K. Mannaerts
HWHessel Wijkstra
Hessel Wijkstra

4 February 2016 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
MGMaudy Gayet
Maudy Gayet
AAAnouk van der Aa
Anouk van der Aa
PSPeter Schmitz
Peter Schmitz
HBHarrie P. Beerlage
Harrie P. Beerlage
BSBart Ph. Schrier
Bart Ph. Schrier
HWHessel Wijkstra
Hessel Wijkstra

16 April 2019 in BMC Urology
Verified
Journal Article
Open access
PDF file
AAAnouk Anna Maria Arnoldus van der Aa
Anouk Anna Maria Arnoldus van der Aa
CMChristophe Koenraad Mannaerts
Christophe Koenraad Mannaerts
MGMaudy C. W. Gayet
Maudy C. W. Gayet
JLJohannes Cornelis van der Linden
Johannes Cornelis van der Linden
BSBarthold Philip Schrier
Barthold Philip Schrier
HWHessel Wijkstra
Hessel Wijkstra
To overcome the limitations regarding two dimensional (2D) greyscale (GS) transrectal ultrasound (TRUS)-guided biopsy in prostate cancer (PCa) detection and tissue packaging in biopsy processing, there is an ongoing focus on new imaging and pathology techniques. A three-dimensional (3D) model of the prostate with biopsy needle guidance can be generate by the Navigo™ workstation (UC-care, Israel). The SmartBX™ system (UC-care, Israel) provides a prostate biopsy core preembedding method. The aim of this study was to compare cancer detection rates between the 3D TRUS-guidance and preembedding method with conventional 2D GS TRUS-guidance among patients undergoing prostate biopsies. We retrospectively analyzed the records of all patients who underwent prostate biopsies for PCa detection at our institution from 2007 to 2016. The cohort was divided into a 2D GS TRUS-guidance cohort (from 2007 to 2013, n = 1149) and a 3D GS TRUS-guidance with preembedding cohort (from 2013 to 2016, n = 469). Effect of 3D GS TRUS-guidance with preembedding on detection rate of PCa and clinically significant PCa (Gleason score ≥ 7 or > 2 biopsy cores with a Gleason score 6) was compared to 2D GS TRUS-guidance using regression models. Detection rate of PCa and clinically significant PCa was 39.0 and 24.9% in the 3D GS TRUS cohort compared to 33.5 and 19.0% in the 2D GS TRUS cohort, respectively. On multivariate regression analysis the use of 3D GS TRUS-guidance with preembedding was associated with a significant increase in detection rate of PCa (aOR = 1.33; 95% CI: 1.03–1.72) and clinically significant PCa (aOR = 1.47; 95% CI: 1.09–1.98). Our results suggest that 3D GS TRUS-guidance with biopsy core preembedding improves PCa and clinically significant PCa detection compared to 2D GS TRUS-guidance. Additional studies are needed to justify the application of these systems in clinical practice.

3 April 2020 in Prostate Cancer
Verified
Journal Article
Open access
PDF file
MGMaudy C. W. Gayet
Maudy C. W. Gayet
AAAnouk A. M. A. van der Aa
Anouk A. M. A. van der Aa
HBHarrie P. Beerlage
Harrie P. Beerlage
BSBart Ph Schrier
Bart Ph Schrier
MGMaaike Gielens
Maaike Gielens
HWHessel Wijkstra
Hessel Wijkstra
Objective. To compare prostate cancer detection rates (CDRs) and pathology results with targeted prostate biopsy (TB) and systematic prostate biopsy (SB) in biopsy-naive men. Methods. An in-patient control study of 82 men undergoing SB and subsequent TB in case of positive prostate MRI between 2015 and 2017 in the Jeroen Bosch Hospital, the Netherlands. Results. Prostate cancer (PCa) was detected in 54.9% with 70.7% agreement between TB and SB. Significant PCa (Gleason score ≥7) was detected in 24.4%. The CDR with TB and SB was 35.4% and 48.8%, respectively ( p = 0.052 ). The CDR of significant prostate cancer with TB and SB was both 20.7%. Clinically significant pathology upgrading occurred in 7.3% by adding TB to SB and 22.0% by adding SB to TB. Conclusions. There is no statistically significant difference between CDRs of SB and TB. Both SB and TB miss significant PCas. Moreover, pathology upgrading occurred more often by adding SB to TB than vice versa. This indicates that the omission of SB in this study population might not be justified.